Apollo Hospitals Enterprise Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong quarter on pricing and complexity: Healthcare Services revenue grew 14% YoY, driven by a balanced 5% volume, 4% case mix, and 5% pricing mix, with surgical volumes up 6% and CONGO-T specialties up 16%.
• Digital profitability delayed by accounting, not operations: Cash EBITDA breakeven pushed to Q1 FY27 solely due to a ~INR 17 crore insurance commission deferral; underlying CM1 is positive and improving, and hospital attribution revenue resumes next quarter.
• New bed ramp-up is the margin story: ~1,500 beds opening over the next two fiscals carry an estimated INR 150 crore start-up loss next year, with quarterly losses potentially hitting INR 50 crore, offset by existing hospital margin expansion of at least 100 bps.
• Keimed merger on track, combined target set: CCI and SEBI approvals obtained, NCLT hearing started; management targets a combined entity run rate of INR 25,000 crore with 7% EBITDA by Q4 FY27.
• What to watch next quarter: Whether the digital business hits cash EBITDA breakeven in Q1 FY27 as promised, the pace of new bed operationalization and occupancy ramp, and any update on the Keimed associate buyout that management sidestepped.

Revenue Drivers & Payer Strength

• CONGO-T specialties lead: Cardiac, oncology, neurosciences, gastroenterology, orthopedics, and transplant delivered 16% YoY revenue growth, lifting surgical volumes 6% and driving the case-mix component of ARPOB growth.
• ARPOB up on clinical intensity: Average revenue per patient rose to INR 180,917 from INR 173,246 QoQ, reflecting higher complexity cases and a 5% effective price realization that includes insurance contract resets, not just tariff increases.
• Payer mix resilient: Insurance and cash patients together account for 83% of inpatient hospital revenues, a share management calls a marker of strength.
• Cluster IP volume moderation deliberate: West, North, and East clusters saw inpatient volumes moderate YoY as management optimized for revenue quality, particularly at the Navi Mumbai unit where the focus shifted to higher specialty care.
• Pan-India presence as competitive moat: Management attributes Q3 outperformance versus more regionally focused peers to nationwide reach, higher CONGO-T complexity, and price realization that began in Q2.

Suneeta Reddy: "We are pleased to report a strong performance during what is typically a seasonally weak quarter."

Digital Business: Profitability Deferred, Not Derailed

• Cash EBITDA breakeven pushed one quarter: A GST-driven change in health insurance commission recognition forced deferral of ~INR 17 crore in revenue over 12 months, shifting the breakeven target from Q4 FY26 to Q1 FY27.
• Underlying unit economics improving: CM1 turned positive last quarter and improved further in Q3; discounts are stabilizing, average order value rose INR 111 net of GST, delivery costs are falling, and marketing spend remains frugal.
• Hospital attribution revenue paused, not lost: Revenue recognition for digital campaigns and attribution from the hospital business was paused this quarter due to a model change; management says it will reactivate next quarter.
• 24/7 GMV growth optically depressed: Reported GMV growth of 15% masks two structural changes: a GST reduction costing INR 30-35 crore per quarter, and the closure of the Amazon channel (INR 160 crore full-year base in FY25). Excluding both, revenue grew 32%.
• IP/OP model shifted to fixed fee: The commercial arrangement with hospitals moved from a variable pay model to a flat quarterly fee for providing the tech platform across the Apollo ecosystem, changing GMV comparability.
• Full digital EBITDA guidance withheld: Management declined to provide an overall digital EBITDA breakeven timeline including ESOP costs, saying it will share a full plan after the annual operating exercise in the Q4 call.

Madhivanan B.: "So we are on our course. On our -- the forecast about our ability to close it in Q4, given this insurance story, which has sort of pushed us back by around INR17-odd crore, given this mismatch of our revenue recognition, we will be able to close this loop in Q1 of FY '27."

Bed Expansion & the Margin Bridge

• Four new hospitals next fiscal: Hyderabad, Kolkata, Bangalore (Belenus/Sarjapur), and Gurgaon will be commissioned, with Gurgaon delayed to Q2 FY27 due to environmental-related construction issues.
• Phased commissioning spreads the drag: Roughly half of ~1,500 new beds open in the upcoming fiscal year, the balance in early FY28, allowing occupancy-led operating leverage to build as demand scales.
• INR 150 crore start-up loss guided: Management estimates this as the annual headwind from new unit ramp-ups, but acknowledges quarterly lumpiness: a single quarter could see a INR 50 crore loss. The hope is that existing hospital volume and revenue growth defrays the hit.
• Existing hospital margin expansion of at least 100 bps: Management sees the base network exceeding 26% margins next year, driven by length-of-stay reduction via digital investment, seasonal volatility management, and an intentional shift to high-complexity cases in flagship hospitals.
• New bed occupancy assumption: First-year occupancy for new beds is modeled at around 40%, with breakeven on 1,300 beds expected within two years.
• Pune (Athena) loss in Q3: The 75-bed facility operationalized during the quarter carried a INR 15 crore loss, with costs for the full three months but revenues only in the last 1-1.5 months.

A. Krishnan: "So we will have to look at it as in a phased manner. So, we will see that Q1 should have -- so when we are saying at INR150 crore, there will be quarters which will have some higher losses also, right? There could be a quarter where there is a INR50 crore loss, which is coming in."

Madhu Sasidhar: "There are several levers that we are depending on. One is, I think there is a little bit more opportunity on length of stay reduction through operational excellence, a lot of investment in digital technologies that is helping us with that. The second is there is still some volatility, I think, day-to-day, week-wise and seasonal volatility, and we are looking at ways in which we can minimize that volatility. And the third is, of course, a consistent focus on case mix and especially in our flagship hospitals, making sure that there is an intentional shift to high-complexity cases."

Keimed & HealthCo: Merger Progress and Targets

• Regulatory milestones cleared: Competition Commission approval and SEBI approval obtained; the scheme has been filed with NCLT and the hearing has started.
• Subsidiary structure streamlined: Keimed has consolidated its entire subsidiary network into 100% subsidiaries, which will merge into AHLL as part of the demerger.
• INR 25,000 crore combined run rate by Q4 FY27: Management sees no challenge in hitting the top-line number, with a 7% EBITDA target for the combined entity.
• Keimed margin normalized: After two quarters of depressed EBITDA due to restructuring and legal costs, Q3 returned to 3.1%+ operations, achieving 3.3% as aberrations cleared and business efficiencies kicked in.
• Associate buyout question sidestepped: When asked about Keimed buying out associates holding shares in different entities, management answered only about regulatory approvals and did not address the buyout progress.

Pharmacy & Platform Growth

• Physical pharmacy same-store growth at 18%: Store additions running at 600 per annum; management is confident of maintaining this run rate in the near to medium term.
• Platform GMV growth ~28% for FY26: Adjusted for the GST change and Amazon channel closure, full-year GMV growth is approximately 28% versus the prior year.
• Next year GMV growth guided at ~30%: Management expects to sustain around 30% GMV growth in FY27, with consistent quarterly performance around that level this year.
• FMCG consumption improving: Management noted very good improvement in FMCG consumption trends, while pharma remained roughly flat.

Talent & Competitive Position

• Doctor retention not a concern: Management sees Apollo continuing to attract top talent, citing its platform investment in technology, reach, and market share leadership as what doctors want.
• ESOP cost tailwind ahead: Maximum ESOP cost is being consumed in the current year; very little cost remains after this, with full guidance on digital EBITDA including ESOP to come in the Q4 call.
• Employee cost sequential decline explained: Q2 carried two one-offs: a INR 12 crore sick leave encashment provision and an additional PLVP cost from the July increment, neither of which repeated in Q3.

Suneeta Reddy: "Well, I think the reverse is also happening. So I think we should be aware that Apollo will continue to attract the best talent. Because, number one, I think we have created a platform that invests not only in technology, but in terms of reach, in terms of market and market share, we will continue to lead with market share. And I think this is what doctors want."

Guidance & Commitments

Key Metrics